The recommendation of two professional societies1 is putting Roche’s cobas® HPV Test back in the spotlight
The debate among healthcare professionals about the best way to screen women for cervical cancer continues to draw praise from advocates of Roche’s cobas HPV Test as a first-line screening tool, even as those reluctant to adopt it believe it may lead to unnecessary follow-up exams and higher medical costs if Pap testing is replaced.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
You are being directed to another Roche web site.
Click the link above to continue or
The link you have selected will take you outside of the Roche Diagnostics USA website.
Roche is not responsible for the information you are about to view.
Roche may provide financial support to organizations or web sites to which the Roche web site